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We determined the prevalence of type-specific hrHPV infections in the Netherlands on cervical scrapes of 45362 women aged 18–
65 years. The overall hrHPV prevalence peaked at the age of 22 with peak prevalence of 24%. Each of the 14 hrHPV types decreased
significantly with age (P-values between 0.0009 and 0.03). The proportion of HPV16 in hrHPV-positive infections also decreased with
age (OR¼0.76 (10-year scale), 95% CI¼0.67–0.85), and a similar trend was observed for HPV16 when selecting hrHPV-positive
women with cervical intraepithelial neoplasia grade 2 or worse (CIN2þ) (OR¼0.76, 95% CI¼0.56–1.01). In women eligible for
routine screening (age 29–61 years) with confirmed CIN2þ, 65% was infected with HPV16 and/or HPV18. When HPV16/18-
positive infections in women eligible for routine screening were discarded, the positive predictive value of cytology for the detection
of CIN2þ decreased from 27 to 15%, the positive predictive value of hrHPV testing decreased from 26 to 15%, and the predictive
value of a double-positive test (positive HPV test and a positive cytology) decreased from 54 to 41%. In women vaccinated against
HPV16/18, screening remains important to detect cervical lesions caused by non-HPV16/18 types. To maintain a high-positive
predictive value, screening algorithms must be carefully re-evaluated with regard to the screening modalities and length of the
screening interval.
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Infection with high-risk human papillomavirus (hrHPV) is the
necessary cause of cervical cancer (Munoz et al, 2003). Prophy-
lactic vaccines are now available that are effective against incident
and persistent HPV16 and 18 infections (Koutsky et al, 2002;
Munoz et al, 2003; Harper et al, 2006; Villa et al, 2006). Mass
vaccination can have a substantial impact on the cervical cancer
incidence, even in developed countries where the incidence is
already low because of implementation of organised cervical
screening. To make a well-judged decision about the future role of
both vaccination and screening in cervical cancer prevention,
detailed information about type-specific hrHPV distribution is
required. Data on hrHPV prevalence and type distribution in the
Netherlands have been reported previously, but only for a
relatively small cohort of 3305 women (Jacobs et al, 2000a; Clifford
et al, 2005). To obtain reliable estimates of the hrHPV type
distribution in relation to age, both for women with normal and
for women with abnormal cytology, data from a far larger cohort
are needed. In this study, we determined the age-dependent
prevalence of 14 hrHPV types and the age-dependent type
distribution within hrHPV-positive women from a cohort of
45362 women in the Netherlands aged 18–65 years. The results
from the current study give an impression of the potential benefits
that can be achieved from HPV16/18 vaccination. They can also be
used to gain insight into the effects of partial cross-protection
against HPV types 31 and 45 (Harper et al, 2006). Furthermore, the
figures will serve as inputs for simulation models in which
different vaccination and screening strategies will be compared.
MATERIALS AND METHODS
Data
Data from 45362 Dutch women between 18 and 65 years of age
were collected. Cohort participants were recruited from GP
practices in the larger Amsterdam area between 1999 and 2002.
Women between 29 and 61 years of age (n¼44102) participated in
the POBASCAM study, a randomised controlled population-based
screening trial evaluating the implementation of hrHPV testing
in cervical screening (Bulkmans et al, 2004). The POBASCAM
trial was approved by both the Medical Ethics Committee of
the VU University Medical Center (no. 96/103) and the Ministry
of Public Health (VWS no. 328650) and has been registered
as an International Standard Randomised Controlled Trial
(ISRCTN20781131). Women younger than 29 years (n¼1109) or
older than 61 years (n¼151) obtained a cervical smear for
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yopportunistic screening. All women underwent cytological testing
as well as hrHPV testing. Women with abnormal cytology or
cervical intraepithelial neoplasia (CIN) in the previous 2 years
were excluded.
Cytology, hrHPV DNA testing, genotyping
Conventional cytological smears were collected and read according
to the CISOE-A classification used in the Netherlands. Translation
into the Bethesda 2001 classification is easy (Bulk et al, 2004).
Cytological results were grouped as normal or borderline mild
dyskaryosis (BMD), and 4BMD. Cervical scrapes were tested for
the presence of hrHPV DNA using the consensus GP5þ/6þ-PCR-
EIA method, which detects 14 hrHPV types (HPV16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66, and 68) (Jacobs et al, 1997). hrHPV
testing was blinded to the cytological result. hrHPV-positive
samples were subjected to hrHPV typing by reverse line blot
analysis of PCR products (van den Brule et al, 2002). Of screening-
eligible women who participated in the POBASCAM trial (aged
29–61 years), histological results of biopsy specimen taken at
colposcopy inspection were included. All cases of CIN were
included that were found after the referral smear (baseline smear
or repeat smear at 6 or 18 months) and within 3 years after
baseline. Cases were classified as CIN 1, 2, or 3 or invasive cancer
in the local hospital and were not subjected to revision.
Statistical methods
Age-specific estimates of the hrHPV prevalence (10-year age
groups) were computed for all women and for women with normal
cytology. Overall and type-specific hrHPV prevalences were related
to age by logistic regression analyses. To obtain smooth functions
of age, cubic splines with knots at age 30 and 50 years were used
(Wold, 1974). The uncertainty about the estimated splines was
represented by 99% point wise correct confidence intervals. Within
the subset of hrHPV-positive women, the effect of age on the type
distribution was assessed by logistic regression analyses. In
statistical tests, only screening-eligible women (age 29–61 years)
were included. Separate analyses were performed for women
without confirmed CIN2þ and for women with confirmed
CIN2þ. The analyses were repeated for women with single
infections.
With vaccination in mind, particular attention was paid to HPV
types 16, 18, 31, and 45. Types 31 and 45 are of interest because
vaccination against 16/18 may result in partial immunity for 31
and 45 through cross-protection (Harper et al, 2006). Within the
group of screening-eligible hrHPV-positive women, we estimated
the type distribution of HPV16, 18, 31, 45 vs other types. Separate
calculations were carried out for women without confirmed
CIN2þ and women with confirmed CIN2þ. This was carried
out by hierarchically assigning women to (1) HPV16, (2) HPV18
without the presence of HPV16, (3) HPV31 or 45 without HPV16
or 18, or (4) none of the HPV types 16, 18, 31, or 45. This means
that, for example, assignment to HPV16 was carried out
independently of whether a woman was simultaneously infected
with other HPV types. Analyses were repeated for women with
single infections.
Vaccination against HPV types 16 and 18 will affect current
screening practice, because a decrease in the prevalence of high-
grade CIN is expected to lead to a decrease in the positive
predictive value of a screening instrument. To gain insight
into the potential effects of vaccination on the predictive value
of a positive screening test, we computed the positive predictive
values for detection of CIN2þ for women without HPV16 and 18.
We computed separate predictive values of positive cytology, a
positive HPV DNA test, and a double-positive test (positive
HPV test and a positive cytology). Notably, the double-positive
test result is a prerequisite for colposcopy referral in a
screening setting where cytology is used as a triage tool in HPV-
positive women. The analyses were repeated for women without
HPV16, 18, 31, and 45. The positive predictive values were adjusted
for women who did not attend repeat screening by Kaplan–Meier
estimation.
RESULTS
Table 1 shows the age-specific estimates of the hrHPV prevalences,
for all women combined and for women with normal cytology.
Table 1 shows the number of women in each age group who are
infected with each of the 14 HPV types. The overall hrHPV
prevalence was 5.6%. In women with normal cytology, the hrHPV
prevalence was 4.0%. HPV16 was the most common type (1.8% in
all women, 1.1% in normal cytology), followed by types 31 and 18.
The hrHPV prevalence in all women aged 29–61 years decreased
Table 1 The hrHPV prevalences in 10-year age-groups, for all women combined (n¼45362) and for women with normal cytology (n¼43737)
Age-
group n
Total
hrHPV (%) HPV16 HPV18 HPV31 HPV33 HPV35 HPV39 HPV45 HPV51 HPV52 HPV56 HPV58 HPV59 HPV66 HPV68
All women
18–24 482 102 (21.2) 36 11 15 6463 1 38 1 44 5 1 4 0
25–34 10828 1161 (10.7) 419 127 174 76 48 67 78 93 93 79 65 26 76 17
35–44 15303 753 (4.9) 235 60 112 48 39 39 65 46 36 52 53 14 30 15
45–54 11556 321 (2.8) 80 37 36 18 12 8 22 21 19 34 16 8 24 1
55–65 7193 184 (2.6) 49 14 23 14 10 6 6 15 7 20 11 5 10 4
Total 45362 2521 (5.6) 819 249 360 162 113 126 174 188 163 199 149 58 154 37
Women with normal cytology
18–24 440 80 (18.2) 31 6 11 445395 1 12 4 9 0
25–34 10238 770 (7.5) 246 81 127 38 31 44 50 62 55 53 41 18 60 9
35–44 14751 508 (3.4) 132 39 76 31 29 25 48 26 23 39 35 13 19 11
45–54 11239 244 (2.2) 52 26 26 13 7 5 19 10 17 30 11 8 19 1
55–65 7069 156 (2.2) 41 11 19 11 10 6 6 9 5 20 10 5 10 4
Total 43737 1758 (4.0) 502 163 259 97 81 85 126 116 105 153 99 48 117 25
In each age group, the number of women that is infected with each of the 14 HPV types is shown.
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and 0.03). Significance could also be demonstrated when selecting
only those women with normal cytology.
Figure 1 shows the age-dependent overall hrHPV prevalence for
all women irrespective of cytological status (Figure 1A) and for
women with normal cytology (Figure 1B). The dashed lines
represent the lower and upper 99% confidence bands of the fitted
curves. Age-specific estimates (10-year age groups) and 99%
confidence intervals were also included in the figures. Overall
hrHPV prevalence peaked at 22 years, with a peak prevalence of
24%. Beyond 45 years, the hrHPV prevalence reached a plateau of
3%. For normal cytology, a similar pattern was observed with a
slightly lower peak prevalence of 20% (Figure 1B). The fitted
curves lie within the 99% confidence intervals of the age-specific
estimates. Because only a small sample of young women (18–24
years) was included in the data, wide confidence intervals were
found in this age group. Figure 2 shows separately fitted
prevalence curves for hrHPV types 16, 18, 31, and 45 in women
with normal cytology. Again, the functions were single-peaked
with peaks before age 30 years.
Within the set of hrHPV-positive screening-eligible women (age
29–61 years) with a valid HPV typing result, the proportion of
HPV16 infections decreased significantly with age (OR¼0.76 (10-
year scale), 95% CI¼0.67–0.85, Po0.001). For HPV39 and
HPV52, a marginal decrease with age was found as well (both
P-values 0.03). In the subset of women with confirmed CIN2þ, the
association between HPV16 and age was in the same direction
(OR¼0.76, 95% CI¼0.56–1.01, P¼0.06). No relationship
between hrHPV type and age was observed for any of the other
types. The impact of age on the proportion of HPV16 infections in
hrHPV-positive women is illustrated in Figure 3. In women with
confirmed CIN2þ, the proportion of HPV16 infections decreased
from 59% in women younger than 40 years to 53% in older
women. The results for women with single infections were nearly
identical.
In hrHPV-positive women who were eligible for routine
screening, 33% was infected with HPV16, 9% was infected with
HPV18 without 16, and 59% was infected with HPV16, 18, 31, and/
or 45. HrHPV infections with types other than HPV16, 18, 31, and/
or 45 were found in 41% of the women. Figure 4 shows the type
distribution in screening-eligible hrHPV-positive women with
confirmed CIN2þ and in women without confirmed CIN2þ.
In women with confirmed CIN2þ, HPV16 and/or HPV18 was
found in 65% of the women. Women with infections other than
HPV16, 18, 31, or 45 comprised 24% of the women with confirmed
CIN2þ. The type distribution in women with single infections was
very similar.
Figure 5 shows the positive predictive values for detection of
CIN2þ lesions in women aged 29–61 years eligible for routine
screening, in case screening is carried out by means of cytology,
HPV testing or both cytology and HPV testing. The black bars
represent the predictive values for the current HPV type
distribution. The predictive values of abnormal cytology and a
positive hrHPV test for detection of CIN2þ were 27 and 26%,
respectively. The predictive value of positive results on both tests
was 54%. When excluding HPV16- and HPV18-positive infections
from the data, the predictive values of positive cytology, positive
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Figure 2 The relationship between the prevalence of HPV types 16, 18,
31, and 45 and age for women with normal cytology (n¼43875).
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Figure 3 The proportion of HPV16 in hrHPV infections in women
younger than 40 years of age and older women. Results are given for
women without confirmed CIN2þ and for women with confirmed
CIN2þ.
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Figure 1 The relationship between hrHPV prevalence and age for all
women (n¼45362) (A) and for women with normal cytology
(n¼43737) (B).
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41%, respectively. When excluding all HPV16/18/31/45-positive
infections, the positive predictive values became 11, 15, and 41%,
respectively.
DISCUSSION
In this study, data from a cohort of 45362 Dutch women between
18 and 65 years of age were used to estimate the relationship
between type-specific hrHPV prevalence and age in the Netherlands.
We have shown that the prevalence of hrHPV peaks between 20
and 25 years, and we estimated the peak prevalence at 24%.
Furthermore, we have shown that the proportion of HPV16
infections in hrHPV-positive smears decreases with age. We
estimated that around 65% of hrHPV-positive women with a
confirmed CIN2þ have an HPV16 and/or 18 infection. This
indicates that non-HPV16/18 infections remain important with
HPV16/18 vaccination.
The data set consisted of women aged 29–61 years eligible for
routine screening and women younger than 29 or older than 61
years outside the routine screening age range. The hrHPV
prevalence in women outside the routine screening age range
may be biased because they visited their GP on own initiative.
However, comparison of the HPV prevalence in opportunistically
screened women aged 27 or 28 years to screening-eligible women
aged 29 or 30 years did not show a trend shift in HPV prevalence
(data not shown). Moreover, we observed an overall hrHPV
prevalence of 21% in the age group 18–24 years, which is
consistent with the international literature (Winer et al, 2003;
Manhart et al, 2006; Cuzick et al, 2006).
Regarding the relationship between the hrHPV prevalence and
age, we observed high prevalences at young age, and a subsequent
decrease until 45 years of age. Above 45 years, the hrHPV
prevalence reached a plateau level. The decrease in hrHPV
prevalence was also observed for each hrHPV type separately.
This decrease may be related to several factors that have
been discussed in detail in the literature (Jacobs et al, 2000b;
Castle et al, 2006). The observed relationship between hrHPV
prevalence and age is in agreement with data from several
European and North American studies (Jacobs et al, 2000a; Sellors
et al, 2000; de Sanjose et al, 2003; Castle et al, 2005; Ronco et al,
2005; Manhart et al, 2006). In our large data set, we did not find a
second hrHPV peak at age beyond 45 years as detected in several
Latin American countries (Franceschi et al, 2006). Within hrHPV-
positive women, HPV16 and HPV31 were the most prevalent
types. Both types were also the most prevalent ones in an earlier
pooled analysis of data from three European countries (Clifford
et al, 2005).
A remarkable finding of this study is the negative association
between the prevalence of HPV16 in hrHPV infections and age. A
similar negative association was found in women eligible for
routine screening with a confirmed CIN2þ lesion. For the other
HPV types in hrHPV infections, associations with age were zero or
minor. Although, in absolute sense, the decrease in HPV16
infections with age was small, we think that our observation
reveals an interesting effect of cervical screening. HPV16 infections
have a higher chance of progressing to cervical lesions than other
infections; therefore, HPV16 infections also have a higher chance
of being detected during the first round of routine cytological
screening. In that case, the proportion of HPV16 infections will
decrease at older age because the lesions containing the HPV16
infection have been eradicated.
From our results, it can be inferred that the maximum
reductions in hrHPV infections and in CIN2þ lesions that can
be achieved by prophylactic HPV16/18 vaccination would be about
42 and 65%, respectively. When an HPV16/18 vaccine would also
offer full cross-protection against types 31 and 45 (Harper et al,
2006), the maximum reductions in hrHPV infections and in
CIN2þ lesions would be about 60 and 76%, respectively. In
reality, the reductions will be smaller because women with an
HPV16/18/31/45-positive infection may be co-infected with
another type. To summarise, screening remains necessary to
detect at least 20–30% of the CIN2þ cases that cannot be
prevented by prophylactic vaccination.
Implementation of mass vaccination may affect screening
programmes. The primary aim of screening in a vaccinated
population is to detect (pre-)cancerous lesions caused by non-
HPV16/18 infections. We showed that the positive predictive
values of cytology and HPV testing decrease when HPV16/18
infections have been removed from the data. The main reason
for this is that HPV16 has a relatively high prevalence in
hrHPV-positive women with confirmed high-grade CIN. This
diminishes the effect of cervical screening on the incidence
of cervical cancer and may lead to a discussion about the
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Figure 5 The positive predictive values for detection of CIN2þ lesions
in women aged 29–61 years eligible for routine screening in case screening
had been carried out by means of cytology, HPV DNA testing, or both.
Results are shown for the current data set (black bars), when excluding
HPV16/18-positive infections from the data (grey bars), and when
excluding HPV16/18/31/45-positive infections (striped bars).
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Figure 4 The HPV type distribution in hrHPV-positive women eligible
for routine screening. The type distribution is shown separately for women
without confirmed CIN2þ and women with confirmed CIN2þ. hrHPV-
positive women were classified as infected with (1) HPV16, (2) HPV18
without presence of HPV16, (3) HPV31 or 45 without HPV16 nor HPV18,
or (4) none of the HPV types 16, 18, 31, or 45.
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Although formal modelling analyses are required to evaluate the
cost-effectiveness of screening strategies with vaccination,
changes in the length of the screening interval and/or the age at
which screening starts can be anticipated. A related discussion
concerns the choice of the primary screening instrument. Meta-
analyses have shown that, HPV DNA testing has a higher
sensitivity than cytology (Arbyn et al, 2006; Cuzick et al, 2006)
and may be implemented in cervical screening in the future.
In this study, we have shown that on removing HPV16/18
infections, the positive predictive values of HPV testing and
cytology show similar decreases. However, in a population
vaccinated against HPV16/18, additional factors may cause a
further degradation of the positive predictive value of cytology
(Franco et al, 2006). More specifically, a decreasing prevalence of
high-grade CIN may make it increasingly more difficult to
differentiate abnormalities in cervical smears. On the other hand,
we also computed that a high positive predictive value can still be
achieved when cytology is applied only as a triage tool in HPV-
positive women. To illustrate, we computed a CIN2þ detection
rate of about 40% in hrHPV-positive women with abnormal
cytology after removing all HPV16/18/31/45 infections. Such
preliminary calculations indicate that screening in women
vaccinated for HPV16/18 can still be performed with maintenance
of the CIN2þ detection rate after referral. However, screening
algorithms must be carefully re-evaluated with regard to the choice
of the primary and secondary screening modality and length of the
screening interval.
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